Form 6-K — CureVac N.V.: financial results for the second quarter and first half of 2022 (August 18, 2022)

Summary

A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission, Commission File Number 001-39446. It states that on August 18, 2022 the company issued a press release announcing its financial results and business updates for the second quarter and first half of 2022. The information is incorporated by reference into Form F-3, File No. 333-259613, except for statements of the Chief Executive Officer and Chief Financial Officer in the exhibit. The press release is listed as Exhibit 99.1.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE
ISSUER

PURSUANT TO RULE 13a-16
OR 15d-16 OF THE

SECURITIES EXCHANGE ACT
OF 1934

For the month of August 2022

Commission File Number: 001-39446

CureVac N.V.

( Exact Name of Registrant as Specified in Its
Charter )

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F x Form
40-F ¨

Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ¨ No x

Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ¨ No x

On August 18, 2022, CureVac N.V. (the “Company”)
issued a press release announcing the Company’s financial results and business updates for the second quarter and first half
of 2022.

The information included in this Form 6-K (including
Exhibit 99.1, but excluding the statements of the Company’s Chief Executive Officer and Chief Financial Officer contained in Exhibit 99.1
hereto) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CUREVAC N.V.
By: | /s/ Franz-Werner Haas, LLD, LLM
Chief Executive Officer

Date: August 18, 2022

EXHIBIT INDEX

EXHIBIT NO. | DESCRIPTION
99.1 | CureVac N.V. Press Release dated August 18, 2022.

File and source

File

SEC_CVAC_6-K_filed2022-08-18_0001104659-22-092551.htm

Size

12,426 bytes

SHA-256

ce11e7e79a13b5cbc550b84895678630f9954dc9a2cacb44a62775fc68da0f39

Our copy

SEC_CVAC_6-K_filed2022-08-18_0001104659-22-092551.htm

Original

www.sec.gov